-
公开(公告)号：US20220249443A1
公开(公告)日：2022-08-11
申请号：US17718760
申请日：2022-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US10576062B2
公开(公告)日：2020-03-03
申请号：US16038739
申请日：2018-07-18
Applicant: Bristol-Myers Squibb Company
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: C07D401/14 , C07D249/06 , A61K31/27 , A61K31/4192 , A61K31/454 , C07D401/04 , A61K31/41 , C07C62/10
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：USRE49352E1
公开(公告)日：2023-01-03
申请号：US17011592
申请日：2020-09-03
Applicant: Bristol-Myers Squibb Company
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Badu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , A61K31/27 , A61K31/454 , C07D249/06 , C07D401/04 , C07D401/14 , A61K31/41 , C07C62/10
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US11007180B2
公开(公告)日：2021-05-18
申请号：US16732387
申请日：2020-01-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: C07D401/04 , A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , A61K31/41 , C07C62/10
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号：US10071078B2
公开(公告)日：2018-09-11
申请号：US15628104
申请日：2017-06-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: C07D401/04 , A61K31/4192 , A61K31/27 , A61K31/454 , C07D401/14 , C07D249/06 , A61K31/41 , C07C62/10
CPC classification number: A61K31/4192 , A61K31/27 , A61K31/41 , A61K31/454 , C07C62/10 , C07D249/06 , C07D401/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
Patent Agency Ranking
公开(公告)号：US20230390249A1
公开(公告)日：2023-12-07
申请号：US18453431
申请日：2023-08-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04
CPC classification number: A61K31/4192 , C07D401/14 , C07D249/06 , A61K31/27 , A61K31/454 , C07D401/04 , A61K31/41
Abstract: The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.-
7.发明授权公开(公告)号：US11639353B2
公开(公告)日：2023-05-02
申请号：US17212210
申请日：2021-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
IPC: C07D471/04 , A61K31/4375 , A61P1/16 , A61P13/12 , A61P11/00 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
8.发明申请公开(公告)号：US20210246136A1
公开(公告)日：2021-08-12
申请号：US17212210
申请日：2021-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
IPC: C07D471/04 , A61P1/16 , A61P13/12 , A61P11/00 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
公开(公告)号：US10968219B2
公开(公告)日：2021-04-06
申请号：US16347844
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guohua Zhao , Pratik Devasthale , Xiang-Yang Ye , Kumaravel Selvakumar , Suresh Dhanusu , Palanikumar Balasubramanian , Leatte R. Guernon , Rita Civiello , Xiaojun Han , Michael Frederick Parker , Swanee E. Jacutin-Porte
IPC: C07D471/04 , C07D491/04 , C07D519/00 , A61P11/00 , A61P19/10 , A61P35/00 , A61P37/06
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
公开(公告)号：US20170360759A1
公开(公告)日：2017-12-21
申请号：US15628104
申请日：2017-06-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun LI , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC: A61K31/4192 , A61K31/27 , C07D401/04 , A61K31/454 , C07C62/10 , A61K31/41
CPC classification number: A61K31/4192 , A61K31/27 , A61K31/41 , A61K31/454 , C07C62/10 , C07D249/06 , C07D401/04 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.023 seconds)
